<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EXPAREL- bupivacaine injection, suspension, liposomal </strong><br>Pacira Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use EXPAREL<span class="Sup">®</span> safely and effectively.  See full prescribing information for EXPAREL.
			<br><br>EXPAREL (bupivacaine liposome injectable suspension)
			<br>Initial U.S. Approval: 1972
		</span></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration, Injection Instructions (<a href="#KS021bb5a9e59-0f51-11df-8a39-0800200c9a66">2.1</a>)     (11/2014) </p>
<p class="Highlighta">Dosage and Administration, Administration Precautions (<a href="#KS022bb5a9e59-0f51-11df-8a39-0800200c9a66">2.2</a>)     (11/2014) </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">EXPAREL is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (<a href="#KS010bb5a9e59-0f51-11df-8a39-0800200c9a66">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">EXPAREL is intended for single-dose administration only.  The recommended dose of EXPAREL is based on the surgical site and the volume required to cover the area. </p>
<table class="Noautorules" width="95%">
<col align="left" width="33%">
<col align="left" width="33%">
<col align="left" width="34%">
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Surgery</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Dose of EXPAREL</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Volume of EXPAREL</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Bunionectomy</td>
<td class="Botrule Lrule Rrule" align="center">106 mg</td>
<td class="Botrule Lrule Rrule" align="center">8 mL</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Hemorrhoidectomy</td>
<td class="Botrule Lrule Rrule" align="center">266 mg</td>
<td class="Botrule Lrule Rrule" align="center">20 mL</td>
</tr>
</tbody>
</table>
<p class="Highlighta">Inject EXPAREL slowly into soft tissue via infiltration (<a href="#KS021bb5a9e59-0f51-11df-8a39-0800200c9a66">2.1</a>). </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">EXPAREL (bupivacaine liposome injectable suspension)
									<br>20 mL single use vial, 1.3% (13.3 mg/mL) (<a href="#KS030bb5a9e59-0f51-11df-8a39-0800200c9a66">3</a>)
								 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">EXPAREL is contraindicated in obstetrical paracervical block anesthesia (<a href="#KS040bb5a9e59-0f51-11df-8a39-0800200c9a66">4</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products (<a href="#KS051bb5a9e59-0f51-11df-8a39-0800200c9a66">5.1</a>).</li>
<li>Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.  Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations (<a href="#KS051bb5a9e59-0f51-11df-8a39-0800200c9a66">5.1</a>).</li>
<li>Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL (<a href="#KS052bb5a9e59-0f51-11df-8a39-0800200c9a66">5.2</a>).</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#KS062bb5a9e59-0f51-11df-8a39-0800200c9a66">6.2</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pacira Pharmaceuticals, Inc. at 1-855-RX-EXPAREL (1-855-793-9727) or FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>EXPAREL should not be admixed with lidocaine or other non-bupivacaine-based local anesthetics</li>
<li>EXPAREL may be administered after at least 20 minutes or more have elapsed following local administration of lidocaine.</li>
<li>Bupivacaine HCl, when injected immediately before or admixed with EXPAREL, may impact the pharmacokinetic and/or physicochemical properties of the drugs (<a href="#KS070bb5a9e59-0f51-11df-8a39-0800200c9a66">7</a>).</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta">Pregnancy:  Based on animal data, may cause fetal harm.  (<a href="#KS081bb5a9e59-0f51-11df-8a39-0800200c9a66">8.1</a>). </p>
<p class="Highlighta">Pediatric Use:  Safety and effectiveness in pediatric patients below the age of 18 have not been established (<a href="#KS084bb5a9e59-0f51-11df-8a39-0800200c9a66">8.4</a>).<br><br> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 11/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1.	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2.	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Injection Instructions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2  	Administration Precautions</a></h2>
<h2><a href="#section-2.3" class="toc">2.3  	Non-Interchangeability with Other Formulations of Bupivacaine</a></h2>
<h2><a href="#section-2.4" class="toc">2.4  	Dosing in Special Populations</a></h2>
<h1><a href="#section-3" class="toc">3.	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4.	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5.	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  	Warnings and Precautions for Bupivacaine Containing Products</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  	Warnings and Precautions Specific for EXPAREL</a></h2>
<h1><a href="#section-6" class="toc">6.	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  	General</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  	Adverse Reactions Reported in All <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Infiltration Clinical Studies</a></h2>
<h1><a href="#section-7" class="toc">7.  DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8.	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy Category C</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6  	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10.	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11.	DESCRIPTION</a></h1>
<h2><a href="#section-10.1" class="toc">11.1  	Active Ingredient</a></h2>
<h2><a href="#section-10.2" class="toc">11.2  	Lipid Formulation</a></h2>
<h1><a href="#section-11" class="toc">12.	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13.	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14.	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Bunionectomy</a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Hemorrhoidectomy</a></h2>
<h1><a href="#section-14" class="toc">16.	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17.	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="KS010bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-1"></a><p></p>
<h1>1.	INDICATIONS AND USAGE</h1>
<p class="First">EXPAREL is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
<p>EXPAREL has not been studied for use in patients younger than 18 years of age.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="KS020bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-2"></a><p></p>
<h1>2.	DOSAGE AND ADMINISTRATION</h1>
<p class="First">EXPAREL is intended for single-dose administration only.  The recommended dose of EXPAREL is based on the surgical site and the volume required to cover the area.</p>
<table width="600">
<col align="left" width="33%">
<col align="left" width="33%">
<col align="left" width="33%">
<tfoot>
<tr class="First"><td align="left" colspan="3">
<span class="Sup">1</span>Infiltrate 7 mL of EXPAREL into the tissues surrounding the osteotomy and 1 mL into the subcutaneous tissue.</td></tr>
<tr class="Last"><td align="left" colspan="3">
<span class="Sup">2</span>Dilute 20 mL of EXPAREL with 10 mL of saline, for a total of 30 mL, and divide the mixture into six 5 mL aliquots.  Perform the anal block by visualizing the anal sphincter as a clock face and slowly infiltrating one aliquot to each of the even numbers.</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First" valign="middle">
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Surgery</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Dose of EXPAREL</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Volume of EXPAREL</span></td>
</tr>
<tr valign="middle">
<td class="Botrule Lrule Rrule" align="left">Bunionectomy<span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule" align="center">106 mg</td>
<td class="Botrule Lrule Rrule" align="center">8 mL</td>
</tr>
<tr class="Last" valign="middle">
<td class="Botrule Lrule Rrule" align="left">Hemorrhoidectomy<span class="Sup">2</span>
</td>
<td class="Botrule Lrule Rrule" align="center">266 mg</td>
<td class="Botrule Lrule Rrule" align="center">20 mL</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="KS021bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Injection Instructions</h2>
<p class="First">EXPAREL should be injected slowly into soft tissues of the surgical site with frequent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> to check for blood and minimize the risk of intravascular injection.</p>
<ul>
<li>EXPAREL is intended for single-dose infiltration only.</li>
<li>EXPAREL should be administered with a 25 gauge or larger bore needle.</li>
<li>The maximum dosage of EXPAREL should not exceed 266 mg (20 mL, 1.3% of undiluted drug).</li>
<li>Do not administer EXPAREL if the product is discolored.</li>
<li style="border-left:1px solid;"><span class="XmChange">Do not administer EXPAREL if it is suspected that the vial has been frozen or exposed to <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperature</span> (greater than 40°C or 104°F) for an extended period. </span></li>
<li style="border-left:1px solid;"><span class="XmChange">EXPAREL can be administered undiluted or diluted up to 0.89 mg/mL (i.e. 1:14 dilution by volume) with normal (0.9%) sterile saline for injection or lactated Ringer’s solution.</span></li>
<li>Vials of EXPAREL should be inverted multiple times to re-suspend the particles immediately prior to withdrawal from the vial.</li>
<li>Diluted suspensions of EXPAREL should be used within 4 hours of preparation in a syringe.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS022bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-2.2"></a><p></p>
<h2>2.2  	Administration Precautions</h2>
<p class="First">Some physicochemical incompatibilities exist between EXPAREL and certain other drugs. Direct contact of EXPAREL with these drugs results in a rapid increase in free (unencapsulated) bupivacaine, altering EXPAREL characteristics and potentially affecting the safety and efficacy of EXPAREL.  Therefore, admixing EXPAREL with other drugs prior to administration is not recommended [<span class="Italics">See Drug Interactions (<a href="#KS070bb5a9e59-0f51-11df-8a39-0800200c9a66">7</a>)</span>].</p>
<ul>
<li>Non-bupivacaine based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally.  The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more.</li>
<li style="border-left:1px solid;"><span class="XmChange">Bupivacaine HCl, when injected immediately before EXPAREL, may impact the pharmacokinetic and/or physicochemical properties of the drugs if the milligram dose of bupivacaine HCl solution exceeds 50% of the EXPAREL dose.  The toxic effects of these drugs are additive and their administration should be used with caution including monitoring for neurologic and cardiovascular effects related to toxicity [<span class="Italics">See Warnings and Precautions (<a href="#KS051bb5a9e59-0f51-11df-8a39-0800200c9a66">5.1</a>) and Overdosage (<a href="#KS100bb5a9e59-0f51-11df-8a39-0800200c9a66">10</a>)</span>].</span></li>
<li>When a topical antiseptic such as povidone iodine (e.g., Betadine<span class="Sup">®</span>) is applied, the site should be allowed to dry before EXPAREL is administered into the surgical site.  EXPAREL should not be allowed to come into contact with antiseptics such as povidone iodine in solution.</li>
</ul>
<p>Studies conducted with EXPAREL demonstrated that the most common implantable materials (polypropylene, PTFE, silicone, stainless steel, and titanium) are not affected by the presence of EXPAREL any more than they are by saline.  None of the materials studied had an adverse effect on EXPAREL.</p>
<p>When administered in recommended doses and concentrations, bupivacaine HCl does not ordinarily produce irritation or tissue damage and does not cause <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS023bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-2.3"></a><p></p>
<h2>2.3  	Non-Interchangeability with Other Formulations of Bupivacaine</h2>
<p class="First">Different formulations of bupivacaine are not bioequivalent even if the milligram dosage is the same.  Therefore, it is not possible to convert dosing from any other formulations of bupivacaine to EXPAREL and vice versa.</p>
<p>Liposomal encapsulation or incorporation in a lipid complex can substantially affect a drug's functional properties relative to those of the unencapsulated or nonlipid-associated drug.  In addition, different liposomal or lipid-complexed products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component.  Such differences may affect functional properties of these drug products.  Do not substitute.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS024bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-2.4"></a><p></p>
<h2>2.4  	Dosing in Special Populations</h2>
<p class="First">EXPAREL has not been studied in patients younger than 18 years of age, pregnant patients or patients who are nursing.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="KS030bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-3"></a><p></p>
<h1>3.	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">EXPAREL (bupivacaine liposome injectable suspension)</p>
<ul><li>20 mL single use vial, 1.3% (13.3 mg/mL)</li></ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="KS040bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-4"></a><p></p>
<h1>4.	CONTRAINDICATIONS</h1>
<p class="First">EXPAREL is contraindicated in obstetrical paracervical block anesthesia.  While EXPAREL has not been tested with this technique, the use of bupivacaine HCl with this technique has resulted in <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">fetal bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="KS050bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-5"></a><p></p>
<h1>5.	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="KS051bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-5.1"></a><p></p>
<h2>5.1  	Warnings and Precautions for Bupivacaine Containing Products</h2>
<p class="First">The safety and effectiveness of bupivacaine and other amide-containing products depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies.  As there is a potential risk of severe life-threatening adverse effects associated with the administration of bupivacaine, any bupivacaine-containing product should be administered in a setting where trained personnel and equipment are available to promptly treat patients who show evidence of neurological or cardiac toxicity [<span class="Italics">See Overdosage (<a href="#KS100bb5a9e59-0f51-11df-8a39-0800200c9a66">10</a>)</span>].</p>
<p>Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after injection of bupivacaine and other amide-containing products.  <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, incoherent speech, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the mouth and lips, metallic taste, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may be early warning signs of central nervous system toxicity.</p>
<p>Bupivacaine and other amide-containing products should also be used with caution in patients with impaired cardiovascular function because they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.</p>
<p>Injection of multiple doses of bupivacaine and other amide-containing products may cause significant increases in plasma concentrations with each repeated dose due to slow accumulation of the drug or its metabolites, or to slow metabolic degradation.  Tolerance to elevated blood concentrations varies with the status of the patient.</p>
<p>Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, these drugs should be used cautiously in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.  Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.</p>
<p><span class="Bold">Central Nervous System Reactions</span></p>
<p>The incidences of adverse <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic reactions</span> associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient.  Many of these effects may be related to local anesthetic techniques, with or without a contribution from the drug.  Neurologic effects following infiltration of soft tissue may include persistent anesthesia, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, all of which may have slow, incomplete, or no recovery.</p>
<p>Central nervous system reactions are characterized by excitation and/or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.  <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> may occur, possibly proceeding to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.  However, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> may be transient or absent, with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> being the first manifestation of an adverse reaction.  This may quickly be followed by <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> merging into <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.  Other central nervous system effects may be <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and constriction of the pupils.  The incidence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> associated with the use of local anesthetics varies with the procedure used and the total dose administered.</p>
<p><span class="Bold">Cardiovascular System Reactions</span></p>
<p>Toxic blood concentrations depress cardiac conductivity and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, which may lead to <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, sometimes resulting in fatalities.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and arterial blood pressure [<span class="Italics">See Warnings and Precautions (<a href="#KS051bb5a9e59-0f51-11df-8a39-0800200c9a66">5.1</a>) and Overdosage (<a href="#KS100bb5a9e59-0f51-11df-8a39-0800200c9a66">10</a>)</span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p>Allergic-type reactions are rare and may occur as a result of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the local anesthetic or to other formulation ingredients.  These reactions are characterized by signs such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> (including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>), <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, elevated temperature, and possibly anaphylactoid-like symptoms (including severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>).  Cross-sensitivity among members of the amide-type local anesthetic group has been reported.  The usefulness of screening for sensitivity has not been definitively established.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">Chondrolysis</span></span></p>
<p>Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> in patients receiving such infusions.  The majority of reported cases of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have involved the shoulder joint; cases of gleno-humerol <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have been described in pediatric patients and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours.  There is insufficient information to determine whether shorter infusion periods are not associated with these findings.  The time of onset of symptoms, such as <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, and loss of motion can be variable, but may begin as early as the second month after surgery.  Currently, there is no effective treatment for <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span>; patients who have experienced <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS052bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-5.2"></a><p></p>
<h2>5.2  	Warnings and Precautions Specific for EXPAREL</h2>
<p class="First">As there is a potential risk of severe life-threatening adverse effects associated with the administration of bupivacaine, EXPAREL should be administered in a setting where trained personnel and equipment are available to promptly treat patients who show evidence of neurological or cardiac toxicity [<span class="Italics">See Overdosage (<a href="#KS100bb5a9e59-0f51-11df-8a39-0800200c9a66">10</a>)</span>].</p>
<p>Caution should be taken to avoid accidental intravascular injection of EXPAREL.  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred following accidental intravascular injection of bupivacaine and other amide-containing products.</p>
<p>Using EXPAREL followed by other bupivacaine formulations has not been studied in clinical trials.  Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL [<span class="Italics">See Clinical Pharmacology (<a href="#KS123bb5a9e59-0f51-11df-8a39-0800200c9a66">12.3</a>)</span>].</p>
<p>EXPAREL has not been evaluated for the following uses and, therefore, is not recommended for these types of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or routes of administration.</p>
<ul>
<li>epidural</li>
<li>intrathecal</li>
<li>regional nerve blocks</li>
<li>intravascular or intra-articular use</li>
</ul>
<p>EXPAREL has not been evaluated for use in the following patient population and, therefore, it is not recommended for administration to these groups.</p>
<ul>
<li>patients younger than 18 years old</li>
<li>pregnant patients</li>
<li>nursing patients</li>
</ul>
<p>The ability of EXPAREL to achieve effective anesthesia has not been studied.  Therefore, EXPAREL is not indicated for pre-incisional or pre-procedural loco-regional anesthetic techniques that require deep and complete sensory block in the area of administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="KS060bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-6"></a><p></p>
<h1>6.	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="KS061bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-6.1"></a><p></p>
<h2>6.1  	General</h2>
<p class="First">The most commonly encountered acute adverse experiences to bupivacaine and all amide-type local anesthetics that demand immediate counter-measures are related to the central nervous and cardiovascular systems.</p>
<p>High plasma concentrations of bupivacaine can occur from overdosage, unintended intravascular injection, or accumulation of bupivacaine in plasma secondary to decreased hepatic metabolic degradation of the drug or diminished plasma protein binding capacity due to <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, pathologically lowered plasma protein production, or competition with other drugs for protein binding sites.  Although rare, some individuals have a lower tolerance to and are supersensitive to bupivacaine and other amide-type local anesthetics and may rapidly develop signs of toxicity at low doses [<span class="Italics">See Overdosage (<a href="#KS100bb5a9e59-0f51-11df-8a39-0800200c9a66">10</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS062bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-6.2"></a><p></p>
<h2>6.2  	Adverse Reactions Reported in All <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Infiltration Clinical Studies</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of EXPAREL was evaluated in 10 randomized, double-blind, local administration into the surgical site clinical studies involving 823 patients undergoing various surgical procedures.  Patients were administered a dose ranging from 66 to 532 mg of EXPAREL.  In these studies, the most common adverse reactions (incidence greater than or equal to 10%) following EXPAREL administration were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>The common adverse reactions (incidence greater than or equal to 2% to less than 10%) following EXPAREL administration were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> postoperative, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="434894" conceptname="Acute posthemorrhagic anemia">hemorrhagic anemia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">procedural pain</span>.</p>
<p>The less common/rare adverse reactions (incidence less than 2%) following EXPAREL administration were <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">dizziness postural</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, incision site <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="43021830" conceptname="Postoperative hypertension">procedural hypertension</span>, procedural <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">procedural nausea</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">pruritus generalized</span>, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, <span class="product-label-link" type="condition" conceptid="441872" conceptname="Supraventricular premature beats">supraventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, body temperature increased, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span>, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">blood pressure decreased</span>, oxygen saturation decreased, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p><span class="Bold">Neurological and Cardiac Adverse Reactions Reported in All <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Infiltration Clinical Studies</span></p>
<p>In the EXPAREL <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> infiltration studies, adverse reactions with an incidence greater than or equal to 1% in the <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> system organ class following EXPAREL administration were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (6.2%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (3.8%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (2.1%), <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span> (1.5%), and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> (1.3%).  The adverse reactions with an incidence greater than or equal to 1% in the <span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span> system organ class following EXPAREL administration were <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (3.9%) and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (1.6%).</p>
<p><span class="Bold">Adverse Reactions Reported in Placebo-Controlled <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Infiltration Clinical Studies</span></p>
<p>Adverse reactions with an incidence greater than or equal to 2% reported by patients in clinical studies comparing 8 mL EXPAREL 1.3% (106 mg) to placebo and 20 mL EXPAREL 1.3% (266 mg) to placebo are shown in Table 1.</p>
<table width="700">
<caption><span>Table 1:	Treatment-Emergent Adverse Reactions (TEAE) with an Incidence Greater than or Equal to 2%: Placebo Controlled Studies</span></caption>
<tfoot>
<tr class="First"><td colspan="5">
<span class="Sup">a</span>	Study 1: Bunionectomy</td></tr>
<tr><td colspan="5">
<span class="Sup">b</span>	Study 2: Hemorrhoidectomy</td></tr>
<tr class="Last"><td colspan="5">At each level of summation (overall, system organ class, preferred term), patients are only counted once.
												<br>Preferred terms are included where at least 2% of patients reported the event in any treatment group.
												<br>TEAE = treatment-emergent adverse event.
											</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td></td>
<td align="center" colspan="2"><span class="Bold">STUDY 1<span class="Sup">a</span></span></td>
<td align="center" colspan="2"><span class="Bold">STUDY 2<span class="Sup">b</span></span></td>
</tr>
<tr>
<td></td>
<td align="center"><span class="Bold">EXPAREL</span></td>
<td align="center"><span class="Bold">Placebo</span></td>
<td align="center"><span class="Bold">EXPAREL</span></td>
<td align="center"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td valign="bottom"><span class="Bold">System Organ Class
												<br>     Preferred Term</span></td>
<td align="center" valign="bottom"><span class="Bold">8 mL/1.3% (106 mg)
												<br>(N=97)
												<br>n (%)</span></td>
<td align="center" valign="bottom"><span class="Bold">(N=96)
												<br>n (%)</span></td>
<td align="center" valign="bottom"><span class="Bold">20 mL/1.3% (266 mg)
												<br>(N=95)
												<br>n (%)</span></td>
<td align="center" valign="bottom"><span class="Bold">(N=94)
												<br>n (%)</span></td>
</tr>
<tr><td colspan="5"> </td></tr>
<tr>
<td valign="top">Any TEAE</td>
<td align="center" valign="top">53 (54.6)</td>
<td align="center" valign="top">59 (61.5)</td>
<td align="center" valign="top">10 (10.5)</td>
<td align="center" valign="top">17 (18.1)</td>
</tr>
<tr><td colspan="5"> </td></tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></td>
<td align="center" valign="top">41 (42.3)</td>
<td align="center" valign="top">38 (39.6)</td>
<td align="center" valign="top">7 (7.4)</td>
<td align="center" valign="top">13 (13.8)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">39 (40.2)</td>
<td align="center" valign="top">36 (37.5)</td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">1 (1.1)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">27 (27.8)</td>
<td align="center" valign="top">17 (17.7)</td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">4 (4.3)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">1 (1.0)</td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">2 (2.1)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="4245614" conceptname="Bleeding from anus">Anal Hemorrhage</span></td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">3 (3.2)</td>
<td align="center" valign="top">4 (4.3)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="4025947" conceptname="Pain associated with defecation">Painful Defecation</span></td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">5 (5.3)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="4133494" conceptname="Rectal discharge">Rectal Discharge</span></td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">1 (1.1)</td>
<td align="center" valign="top">3 (3.2)</td>
</tr>
<tr><td colspan="5"> </td></tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td align="center" valign="top">20 (20.6)</td>
<td align="center" valign="top">30 (31.3)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">11 (11.3)</td>
<td align="center" valign="top">25 (26.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">5 (5.2)</td>
<td align="center" valign="top">8 (8.3)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">5 (5.2)</td>
<td align="center" valign="top">1 (1.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr><td colspan="5"> </td></tr>
<tr>
<td valign="top">Skin And Subcutaneous Tissue Disorders</td>
<td align="center" valign="top">8 (8.2)</td>
<td align="center" valign="top">7 (7.3)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">Pruritus Generalized</span></td>
<td align="center" valign="top">5 (5.2)</td>
<td align="center" valign="top">6 (6.3)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center" valign="top">3 (3.1)</td>
<td align="center" valign="top">1 (1.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr><td colspan="5"> </td></tr>
<tr>
<td valign="top">Investigations</td>
<td align="center" valign="top">5 (5.2)</td>
<td align="center" valign="top">3 (3.1)</td>
<td align="center" valign="top">4 (4.2)</td>
<td align="center" valign="top">3 (3.2)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine Aminotransferase</span> Increased</td>
<td align="center" valign="top">3 (3.1)</td>
<td align="center" valign="top">3 (3.1)</td>
<td align="center" valign="top">1 (1.1)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate Aminotransferase</span> Increased</td>
<td align="center" valign="top">3 (3.1)</td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     Blood Creatinine Increased</td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     Body Temperature Increased</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">3 (3.2)</td>
<td align="center" valign="top">3 (3.2)</td>
</tr>
<tr><td colspan="5"> </td></tr>
<tr>
<td valign="top">General Disorders And Administration Site Conditions</td>
<td align="center" valign="top">4 (4.1)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">1 (1.1)</td>
<td align="center" valign="top">1 (1.1)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">Feeling Hot</span></td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">1 (1.1)</td>
<td align="center" valign="top">1 (1.1)</td>
</tr>
<tr><td colspan="5"> </td></tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> And <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">1 (1.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infection</span></td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">1 (1.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr><td colspan="5"> </td></tr>
<tr>
<td valign="top">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> And Procedural Complications</td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td valign="top">     Post Procedural <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr><td colspan="5"> </td></tr>
<tr>
<td valign="top">Metabolism And Nutrition Disorders</td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
<tr class="Last">
<td valign="top">     <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span></td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">2 (2.1)</td>
<td align="center" valign="top">0 (0.0)</td>
<td align="center" valign="top">0 (0.0)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="KS070bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-7"></a><p></p>
<h1>7.  DRUG INTERACTIONS</h1>
<p class="First">EXPAREL can be administered undiluted or diluted up to 0.89 mg/mL (i.e., 1:14 dilution by volume) with normal (0.9%) sterile saline for injection or lactated Ringer’s solution.  EXPAREL must not be diluted with water or other hypotonic agents as it will result in disruption of the liposomal particles.</p>
<p>EXPAREL should not be admixed with other local anesthetics. </p>
<p>EXPAREL may be locally administered after at least 20 minutes following local administration of lidocaine.</p>
<p>Bupivacaine HCl, when injected immediately before EXPAREL, may impact the pharmacokinetic and/or physicochemical properties of the drugs if the milligram dose of bupivacaine HCl solution exceeds 50% of the EXPAREL dose.  The toxic effects of these drugs are additive and their administration should be used with caution including monitoring for neurologic and cardiovascular effects related to toxicity [<span class="Italics">See Warnings and Precautions (<a href="#KS051bb5a9e59-0f51-11df-8a39-0800200c9a66">5.1</a>) and Overdosage (<a href="#KS100bb5a9e59-0f51-11df-8a39-0800200c9a66">10</a>)</span>].</p>
<p>EXPAREL should not be admixed with other drugs prior to administration.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="KS080bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-8"></a><p></p>
<h1>8.	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="KS081bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy Category C</h2>
<p class="First Italics Underline">Risk Summary</p>
<p>There are no adequate and well-controlled studies of EXPAREL in pregnant women. Animal reproduction studies have been conducted to evaluate bupivacaine.  In these studies, subcutaneous administration of bupivacaine to rats and rabbits during organogenesis was associated with embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span> in rabbits at a dose equivalent to the maximum recommended human dose (MRHD).  Subcutaneous administration of bupivacaine to rats from implantation through weaning, also at an MRHD-equivalent dose, produced decreased pup survival. EXPAREL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p class="Italics Underline">Clinical Considerations</p>
<p>Labor or Delivery</p>
<p>Bupivacaine is contraindicated for obstetrical paracervical block anesthesia.  While EXPAREL has not been studied with this technique, the use of bupivacaine for obstetrical paracervical block anesthesia has resulted in <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">fetal bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Bupivacaine can rapidly cross the placenta, and when used for epidural, caudal, or pudendal block anesthesia, can cause varying degrees of maternal, fetal, and neonatal toxicity [<span class="Italics">See Clinical Pharmacology (<a href="#KS123bb5a9e59-0f51-11df-8a39-0800200c9a66">12.3</a>)</span>]. The incidence and degree of toxicity depend upon the procedure performed, the type, and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus, and neonate involve alterations of the central nervous system, peripheral vascular tone, and cardiac function.</p>
<p class="Italics Underline">Data</p>
<p>Animal Data</p>
<p>Bupivacaine hydrochloride was administered subcutaneously to rats at doses of 4.4, 13.3, and 40 mg/kg/day and to rabbits at doses of 1.3, 5.8, and 22.2 mg/kg/day during the period of organogenesis (implantation to closure of the hard palate). No embryo-fetal effects were observed in rats at the doses tested with the high dose causing increased maternal lethality. An increase in embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span> was observed in rabbits at the high dose in the absence of maternal toxicity. This dose is clinically relevant as is comparable to the MRHD based on Body Surface Area (BSA) comparisons. </p>
<p>In a rat pre- and post-natal development study conducted at subcutaneous doses of 4.4, 13.3, and 40 mg/kg/day with dosing from implantation through weaning (during pregnancy and lactation), decreased pup survival was observed at the high dose, a clinically relevant dose as it is comparable to the MRHD based on BSA comparisons. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="KS083bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">Published literature reports that bupivacaine is present in human milk at low levels; however, the drug is poorly absorbed orally. Exercise caution when administering EXPAREL to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="KS084bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 18 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="KS085bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">Of the total number of patients in the EXPAREL <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> infiltration clinical studies (N=823), 171 patients were greater than or equal to 65 years of age and 47 patients were greater than or equal to 75 years of age.  No overall differences in safety or effectiveness were observed between these patients and younger patients.  Clinical experience with EXPAREL has not identified differences in efficacy or safety between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>In clinical studies, differences in various pharmacokinetic parameters have been observed between elderly and younger patients. Bupivacaine is known to be substantially excreted by the kidney, and the risk of toxic reactions to bupivacaine may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection of EXPAREL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS086bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-8.5"></a><p></p>
<h2>8.6  	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, these drugs should be used cautiously in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.  Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e1-be50-0800200c9a66-jy87"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Bupivacaine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Care should be taken in dose selection of EXPAREL.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="KS100bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-9"></a><p></p>
<h1>10.	OVERDOSAGE</h1>
<p class="First">Acute emergencies from local anesthetics are generally related to high plasma concentrations encountered during therapeutic use of local anesthetics or to unintended intravascular injection of local anesthetic solution [<span class="Italics">See Warnings and Precautions (<a href="#KS050bb5a9e59-0f51-11df-8a39-0800200c9a66">5</a>) and Adverse Reactions (<a href="#KS060bb5a9e59-0f51-11df-8a39-0800200c9a66">6</a>)</span>].</p>
<p>In the clinical study program, maximum plasma concentration (C<span class="Sub">max</span>) values of approximately 34,000 ng/mL were reported and likely reflected inadvertent intravascular administration of EXPAREL or systemic absorption of EXPAREL at the surgical site. The plasma bupivacaine measurements did not discern between free and liposomal-bound bupivacaine making the clinical relevance of the reported values uncertain; however, no discernable adverse events or clinical sequelae were observed in these patients.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="KS110bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-10"></a><p></p>
<h1>11.	DESCRIPTION</h1>
<p class="First">EXPAREL is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam<span class="Sup">®</span> drug delivery system) containing bupivacaine.  Bupivacaine is present at a concentration of 13.3 mg/mL.  After injection of EXPAREL into soft tissue, bupivacaine is released from the multivesicular liposomes over a period of time.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="KS111bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-10.1"></a><p></p>
<h2>11.1  	Active Ingredient</h2>
<p class="First">Bupivacaine is related chemically and pharmacologically to the amide-type local anesthetics.  It is a homologue of mepivacaine and is related chemically to lidocaine.  All three of these anesthetics contain an amide linkage between the aromatic nucleus and the amino, or piperidine group.  They differ in this respect from the procaine-type local anesthetics, which have an ester linkage.  Chemically, bupivacaine is 1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide with a molecular weight of 288.4.  Bupivacaine has the following structural formula:</p>
<p><img alt="Structural formula of Bupivacaine" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb5a9e59-0f51-11df-8a39-0800200c9a66&amp;name=exparel-figure-1.jpg"></p>
<p>Bupivacaine is present in EXPAREL at a concentration of 13.3 mg/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS112bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-10.2"></a><p></p>
<h2>11.2  	Lipid Formulation</h2>
<p class="First">The median diameter of the liposome particles ranges from 24 to 31 µm.  The liposomes are suspended in a 0.9% sodium chloride solution.  Each vial contains bupivacaine at a nominal concentration of 13.3 mg/mL.  Inactive ingredients and their nominal concentrations are: <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, 4.7 mg/mL; 1, 2-dipalmitoyl-sn-glycero-3 phospho-rac-(1-glycerol) (DPPG), 0.9 mg/mL; tricaprylin, 2.0 mg/mL; and 1, 2-dierucoylphosphatidylcholine (DEPC), 8.2 mg/mL.  The pH of EXPAREL is in the range of 5.8 to 7.4.</p>
<p>Liposomal encapsulation or incorporation in a lipid complex can substantially affect a drug's functional properties relative to those of the unencapsulated or nonlipid-associated drug.  In addition, different liposomal or lipid-complexed products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component.  Such differences may affect functional properties of these drug products.  Do not substitute.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="KS120bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-11"></a><p></p>
<h1>12.	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="KS121bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Local anesthetics block the generation and the conduction of nerve impulses presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential.  In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers.  Clinically, the order of loss of nerve function is as follows: (1) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="KS122bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics</h2>
<p class="First">Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems.  At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, refractoriness, contractility, and peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> are minimal.  However, toxic blood concentrations depress cardiac conductivity and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, which may lead to <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, sometimes resulting in fatalities.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and arterial blood pressure.  Clinical reports and animal research suggest that these cardiovascular changes are more likely to occur after accidental intravascular injection of bupivacaine.</p>
<p>Following systemic absorption, local anesthetics can produce central nervous system stimulation, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or both.  Apparent central stimulation is manifested as <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span> progressing to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, followed by <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> progressing ultimately to <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.  However, the local anesthetics have a primary depressant effect on the medulla and on higher centers.  The depressed stage may occur without a prior excited state.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="KS123bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">Local infiltration of EXPAREL results in significant systemic plasma levels of bupivacaine which can persist for 96 hours [<span class="Italics">See Warnings and Precautions (<a href="#KS052bb5a9e59-0f51-11df-8a39-0800200c9a66">5.2</a>)</span>].  Systemic plasma levels of bupivacaine following administration of EXPAREL are not correlated with local efficacy.</p>
<p><span class="Bold Italics">Absorption</span></p>
<p>The rate of systemic absorption of bupivacaine is dependent upon the total dose of drug administered, the route of administration, and the vascularity of the administration site.</p>
<p>Pharmacokinetic parameters of EXPAREL after local administration were evaluated following surgical procedures.  Descriptive statistics of pharmacokinetic parameters of representative EXPAREL doses in each study are provided in Table 2.</p>
<table width="600">
<caption><span>Table 2:	Summary of Pharmacokinetic Parameters for Bupivacaine after Administration of Single Doses of EXPAREL</span></caption>
<col align="left" width="30%">
<col align="left" width="30%">
<col align="left" width="30%">
<tfoot><tr class="First Last"><td align="left" colspan="3">Note: Arithmetic mean (standard deviation) except T<span class="Sub">max</span> (median).</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" rowspan="3"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><span class="Bold">EXPAREL</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Bunionectomy
												<br>106 mg (8 mL)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Hemorrhoidectomy
												<br>266 mg (20 mL)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">(N=26)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">(N=25)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">C<span class="Sub">max</span> (ng/mL)</td>
<td class="Botrule Lrule Rrule" align="center">166 (92.7)</td>
<td class="Botrule Lrule Rrule" align="center">867 (353)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">T<span class="Sub">max</span> (h)</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
<td class="Botrule Lrule Rrule" align="center">0.5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">AUC<span class="Sub">(0-t)</span> (h×ng/mL)</td>
<td class="Botrule Lrule Rrule" align="center">5864 (2038)</td>
<td class="Botrule Lrule Rrule" align="center">16,867 (7868)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">AUC<span class="Sub">(inf)</span> (h×ng/mL)</td>
<td class="Botrule Lrule Rrule" align="center">7105 (2283)</td>
<td class="Botrule Lrule Rrule" align="center">18,289 (7569)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">t<span class="Sub">½</span> (h)</td>
<td class="Botrule Lrule Rrule" align="center">34.1 (17.0)</td>
<td class="Botrule Lrule Rrule" align="center">23.8 (39.4)</td>
</tr>
</tbody>
</table>
<p><span class="Bold Italics">Distribution</span></p>
<p>After bupivacaine has been released from EXPAREL and is absorbed systemically, bupivacaine distribution is expected to be the same as for any bupivacaine HCl solution formulation.</p>
<p>Local anesthetics including bupivacaine are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain.</p>
<p>Local anesthetics including bupivacaine appear to cross the placenta by passive diffusion.  The rate and degree of diffusion is governed by (1) the degree of plasma protein binding, (2) the degree of ionization, and (3) the degree of lipid solubility.  Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer.  Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).  The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug.  Lipid soluble, non-ionized drugs such as bupivacaine readily enter the fetal blood from the maternal circulation.</p>
<p><span class="Bold Italics">Metabolism</span></p>
<p>Amide-type local anesthetics, such as bupivacaine, are metabolized primarily in the liver via conjugation with glucuronic acid.  Pipecolylxylidine (PPX) is the major metabolite of bupivacaine; approximately 5% of bupivacaine is converted to PPX. Elimination of drug depends largely upon the availability of plasma protein binding sites in the circulation to carry it to the liver where it is metabolized.</p>
<p>Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, especially those with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, may be more susceptible to the potential toxicities of the amide-type local anesthetics.</p>
<p><span class="Bold Italics">Excretion</span></p>
<p>After bupivacaine has been released from EXPAREL and is absorbed systemically, bupivacaine excretion is expected to be the same as for other bupivacaine formulations.</p>
<p>The kidney is the main excretory organ for most local anesthetics and their metabolites.  Only 6% of bupivacaine is excreted unchanged in the urine.</p>
<p>Urinary excretion is affected by urinary perfusion and factors affecting urinary pH.  Acidifying the urine hastens the renal elimination of local anesthetics.  Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, factors affecting urinary pH, and renal blood flow.</p>
<p><span class="Bold Italics">Specific Populations</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The effects of decreased hepatic function on bupivacaine pharmacokinetics following administration of EXPAREL were studied in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  Consistent with the hepatic clearance of bupivacaine, mean plasma concentrations were higher in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> than in the healthy control volunteers with approximately 1.5- and 1.6-fold increases in the mean values for C<span class="Sub">max</span> and the area under the curve (AUC), respectively.</p>
<p>Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, these drugs should be used cautiously in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations [<span class="Italics">See Warnings and Precautions (<a href="#KS051bb5a9e59-0f51-11df-8a39-0800200c9a66">5.1</a>) and Use in Specific Populations (<a href="#KS086bb5a9e59-0f51-11df-8a39-0800200c9a66">8.6</a>)</span>].</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Bupivacaine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Care should be taken in dose selection of EXPAREL [<span class="Italics">See Use in Specific Populations (<a href="#e1-be50-0800200c9a66-jy87">8.7</a>)</span>].</p>
<p><span class="Italics">Age</span></p>
<p>Various pharmacokinetic parameters of the local anesthetics such as bupivacaine can be significantly altered by the age of the patient.</p>
<p>In clinical studies, differences in various pharmacokinetic parameters have been observed between elderly and younger patients.</p>
<p>Bupivacaine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection of EXPAREL [<span class="Italics">See Use in Specific Populations (<a href="#KS085bb5a9e59-0f51-11df-8a39-0800200c9a66">8.5</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="KS130bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-12"></a><p></p>
<h1>13.	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="KS131bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of bupivacaine have not been conducted. The mutagenic potential and the effect on fertility of bupivacaine have not been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="KS140bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-13"></a><p></p>
<h1>14.	CLINICAL STUDIES</h1>
<p class="First">The efficacy of EXPAREL was compared to placebo in two multicenter, randomized, double-blinded clinical trials. One trial evaluated the treatments in patients undergoing bunionectomy; the other trial evaluated the treatments in patients undergoing hemorrhoidectomy.  EXPAREL has not been demonstrated to be safe and effective in other procedures.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="KS141bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Bunionectomy</h2>
<p class="First">A multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluated the safety and efficacy of 106 mg EXPAREL in 193 patients undergoing bunionectomy.  The mean age was 43 years (range 18 to 72).  Study medication was administered directly into the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> at the conclusion of the surgery, prior to <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> closure.  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> intensity was rated by the patients on a 0 to 10 numeric rating scale (NRS) out to 72 hours.  Postoperatively, patients were allowed rescue medication (5 mg oxycodone/325 mg acetaminophen orally every 4 to 6 hours as needed) or, if that was insufficient within the first 24 hours, ketorolac (15 to 30 mg IV).  The primary outcome measure was the area under the curve (AUC) of the NRS <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity scores (cumulative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores) collected over the first 24 hour period.  There was a significant treatment effect for EXPAREL compared to placebo.</p>
<p>In this clinical study, EXPAREL demonstrated a significant reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity compared to placebo for up to 24 hours. The difference in mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity between treatment groups occurred only during the first 24 hours following study drug administration. Between 24 and 72 hours after study drug administration, there was minimal to no difference between EXPAREL and placebo treatments on mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS142bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Hemorrhoidectomy</h2>
<p class="First">A multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluated the safety and efficacy of 266 mg EXPAREL in 189 patients undergoing hemorrhoidectomy.  The mean age was 48 years (range 18 to 86).  Study medication was administered directly into the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> (greater than or equal to 3 cm) at the conclusion of the surgery.  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> intensity was rated by the patients on a 0 to 10 NRS at multiple time points up to 72 hours.  Postoperatively, patients were allowed rescue medication (morphine sulfate 10 mg intramuscular every 4 hours as needed).  The primary outcome measure was the AUC of the NRS <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity scores (cumulative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores) collected over the first 72 hour period.  There was a significant treatment effect for EXPAREL compared to placebo.</p>
<p>In this clinical study, EXPAREL demonstrated a significant reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity compared to placebo for up to 24 hours. The difference in mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity between treatment groups occurred only during the first 24 hours following study drug administration. Between 24 and 72 hours after study drug administration, there was minimal to no difference between EXPAREL and placebo treatments on mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity; however, there was an attendant decrease in opioid consumption, the clinical benefit of which was not demonstrated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="KS160bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-14"></a><p></p>
<h1>16.	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">EXPAREL (bupivacaine liposome injectable suspension) is available in single-use vials for infiltration.</p>
<p>      20 mL single use vial, 1.3% (13.3 mg/mL) packaged in cartons of 10 (NDC 65250-266-20)</p>
<p>Different formulations of bupivacaine are not bioequivalent even if the milligram strength is the same.  Therefore, it is not possible to convert dosing from any other formulations of bupivacaine to EXPAREL.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="KS161bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>EXPAREL vials should be stored refrigerated between 2°C to 8°C (36°F to 46°F).  EXPAREL may be held at a controlled room temperature of 20°C to 25°C (68°F to 77°F) for up to 30 days in sealed, intact (unopened) vials.  Vials should not be re-refrigerated.  As a convenience to the hospital pharmacist, each vial label includes space to record the date when the vial has been removed from refrigeration.</p>
<p>EXPAREL should not be frozen or exposed to <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperatures</span> (greater than 40°C or 104°F) for an extended period.  Do not administer EXPAREL if it is suspected of having been frozen or exposed to <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperatures</span>.  Do not use the vial if the stopper is bulging. </p>
<p><span class="Bold">Handling</span></p>
<ul>
<li>Vials of EXPAREL should be inverted to re-suspend the particles immediately prior to withdrawal from the vial.  Multiple inversions may be necessary to re-suspend the particles if the contents of the vial have settled.</li>
<li>Vials should be visually inspected before use.</li>
<li>Do not filter.</li>
<li>Do not heat before use.</li>
<li>Do not autoclave.</li>
<li>EXPAREL should be administered with a 25 gauge or larger bore needle.</li>
<li>EXPAREL can be administered undiluted or diluted up to 0.89 mg/mL (i.e. 1:14 dilution by volume) with normal (0.9%) sterile saline for injection or lactated Ringer’s solution. </li>
<li>Following withdrawal from the vial, EXPAREL may be stored at controlled room temperature of 20°C to 25°C (68°F to 77°F) for up to 4 hours prior to administration.</li>
<li>Discard any unused portion in an appropriate manner.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="KS170bb5a9e59-0f51-11df-8a39-0800200c9a66"></a><a name="section-15"></a><p></p>
<h1>17.	PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be informed in advance that bupivacaine-containing products can cause temporary <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">loss of sensation</span> or motor activity in the area infiltrated. Physicians should discuss adverse reactions in the EXPAREL prescribing information with their patients.</p>
<br><p>Pacira Pharmaceuticals, Inc.</p>
<p>San Diego, CA 92121   USA</p>
<p>Patent Numbers:</p>
<p>6,132,766</p>
<p>5,766,627</p>
<p>5,891,467</p>
<p>8,182,835</p>
<p>Trademark of Pacira Pharmaceuticals, Inc.</p>
<p>PACIRA
							<br>PHARMACEUTICALS, INC.
						</p>
<p>For additional information call 1-855-RX-EXPAREL (1-855-793-9727)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="e1-be50-0800200c9a66-jy-plpdp3"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Package Label - Exparel 20 mL Vial Label</span></p>
<p><img alt="Package Label - Exparel 20 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb5a9e59-0f51-11df-8a39-0800200c9a66&amp;name=exparel-figure-2.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="e1-be50-0800200c9a66-jy-plpdp4"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Package Label - Exparel 20 mL Carton Label</span></p>
<p><img alt="Package Label - Exparel 20 mL Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb5a9e59-0f51-11df-8a39-0800200c9a66&amp;name=exparel-figure-3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXPAREL 		
					</strong><br><span class="contentTableReg">bupivacaine injection, suspension, liposomal</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65250-266</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INFILTRATION</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BUPIVACAINE</strong> (BUPIVACAINE) </td>
<td class="formItem">BUPIVACAINE</td>
<td class="formItem">13.3 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65250-266-20</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022496</td>
<td class="formItem">01/01/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pacira Pharmaceuticals Inc.
							(783298615)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pacira Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">783298615</td>
<td class="formItem">MANUFACTURE(65250-266)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Packaging Coordinators, LLC</td>
<td class="formItem"></td>
<td class="formItem">078525133</td>
<td class="formItem">REPACK(65250-266)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f4fbc668-4092-4056-96d6-37a98126aa53</div>
<div>Set id: bb5a9e59-0f51-11df-8a39-0800200c9a66</div>
<div>Version: 6</div>
<div>Effective Time: 20150422</div>
</div>
</div> <div class="DistributorName">Pacira Pharmaceuticals Inc.</div></p>
</body></html>
